Metrics as of 10/15/2026, 02:19 PM (Berlin time), refresh in progress.
Passage Bio Stock
Passage Bio, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- William Chou
- Employees
- 24
- Market cap
- $12 M
- IPO
- 28/02/2020
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which…
Passage Bio stock: price history
1D
-1.6%
1W
-4.8%
1M
-24.5%
6M
-69.2%
YTD
-69.5%
1Y
-57.8%
2Y
-69.0%
5Y
-98.2%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~1% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Passage Bio
Analyst assessment of Passage Bio
PRICE TARGET LOW
US$7.00
CONSENSUS
US$10.00
MEDIAN
US$8.00
PRICE TARGET HIGH
US$15.00
0
STRONG BUY
6
BUY
5
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 21/04/2026
Passage Bio stock metrics
P/E
-0.32
P/B
2.59
EV/EBITDA
0.38
RETURN ON EQUITY
-175.5%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
92.3%
FLOAT SHARES
2,969,630
AVG. DAILY VOLUME (30D)
26,690
Insider transactions (SEC)
Lynx1 Capital Management LP
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Passage Bio stock
What does Passage Bio do?
Passage Bio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is William Chou, the company employs around 24 people.
The IPO was on 28/02/2020; the stock trades on NASDAQ under the ticker PASG.
What do analysts say about Passage Bio stock?
11 analysts rate the stock, the consensus is Buy (as of 21/04/2026).
The average price target is US$10.00, ranging from US$7.00 to US$15.00, with a median of US$8.00.
This is an external assessment, not a statement by Market Jury.
When does Passage Bio report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 1% stronger than usual.
Does Passage Bio pay a dividend?
No, Passage Bio currently does not pay a dividend.
Which stocks are comparable to Passage Bio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Passage Bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess Passage Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.